BR112019005505A2 - sal pidolato ou sal malato, composição farmacêutica, método para preparar um sal, uso de quantidade terapeuticamente eficaz de sal e uso de um sal pidolato ou sal malato - Google Patents

sal pidolato ou sal malato, composição farmacêutica, método para preparar um sal, uso de quantidade terapeuticamente eficaz de sal e uso de um sal pidolato ou sal malato

Info

Publication number
BR112019005505A2
BR112019005505A2 BR112019005505A BR112019005505A BR112019005505A2 BR 112019005505 A2 BR112019005505 A2 BR 112019005505A2 BR 112019005505 A BR112019005505 A BR 112019005505A BR 112019005505 A BR112019005505 A BR 112019005505A BR 112019005505 A2 BR112019005505 A2 BR 112019005505A2
Authority
BR
Brazil
Prior art keywords
salt
pidolate
malate
preparing
pharmaceutical composition
Prior art date
Application number
BR112019005505A
Other languages
English (en)
Inventor
Sun Kim Eun
Chul Yoo Hyung
Sun Kim Jae
Do Choi Kwang
Kyoung Lee Min
Ah LEE Sung
Original Assignee
Cj Healthcare Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cj Healthcare Corp filed Critical Cj Healthcare Corp
Publication of BR112019005505A2 publication Critical patent/BR112019005505A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

a presente invenção refere-se aos sais pidolato e malato de um composto representado pela fórmula química 1 e métodos de preparação da mesma, em que o composto tem usos preventivos e terapêuticos para uma doença mediada por atividade antagonística de bomba de ácido e tem excelente estabilidade de fase líquida, estabilidade de fase sólida, solubilidade em água, estabilidade na precipitação e higroscopicidade.
BR112019005505A 2016-09-21 2017-09-20 sal pidolato ou sal malato, composição farmacêutica, método para preparar um sal, uso de quantidade terapeuticamente eficaz de sal e uso de um sal pidolato ou sal malato BR112019005505A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020160120996A KR101829706B1 (ko) 2016-09-21 2016-09-21 벤즈이미다졸 유도체의 산부가염
PCT/KR2017/010332 WO2018056697A1 (ko) 2016-09-21 2017-09-20 벤즈이미다졸 유도체의 산부가염

Publications (1)

Publication Number Publication Date
BR112019005505A2 true BR112019005505A2 (pt) 2019-06-04

Family

ID=61387666

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019005505A BR112019005505A2 (pt) 2016-09-21 2017-09-20 sal pidolato ou sal malato, composição farmacêutica, método para preparar um sal, uso de quantidade terapeuticamente eficaz de sal e uso de um sal pidolato ou sal malato

Country Status (14)

Country Link
US (3) US11535610B2 (pt)
EP (1) EP3517528B1 (pt)
JP (1) JP6814891B2 (pt)
KR (1) KR101829706B1 (pt)
CN (1) CN109769392B (pt)
AR (1) AR109679A1 (pt)
BR (1) BR112019005505A2 (pt)
ES (1) ES2896802T3 (pt)
JO (1) JOP20170172B1 (pt)
MX (1) MX2019003171A (pt)
MY (1) MY197242A (pt)
PH (1) PH12019500602A1 (pt)
TW (1) TWI659028B (pt)
WO (1) WO2018056697A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190198A1 (ar) * 2018-08-28 2020-02-28 Hk Inno N Corp تركيبة صيدلانية تشتمل على عامل مضاد للصفيحات ومثبط إفراز حمض معدي
JOP20190201A1 (ar) * 2018-08-29 2020-02-29 Hk Inno N Corp تركيبة لاستئصال الملوية البوابية
EA202192286A1 (ru) * 2019-02-18 2021-11-18 ЭйчКей ИННО.Эн КОРПОРЕЙШН Фармацевтическая композиция, содержащая соединение-производное бензимидазола
BR112022025169A2 (pt) * 2020-06-12 2022-12-27 Hk Inno N Corp Uso de uma composição farmacêutica compreendendo composto derivado de benzimidazol, um sal farmaceuticamente aceitável do mesmo, um hidrato ou solvato do mesmo, ou uma mistura dos mesmos
CN116507318A (zh) * 2020-10-23 2023-07-28 怡诺安有限公司 包含苯并咪唑衍生物化合物的口服崩解片剂及其制备方法
TWI822151B (zh) * 2021-07-02 2023-11-11 南韓商Ｌｇ化學股份有限公司 製備黃嘌呤氧化酶抑制劑的方法
WO2023106841A1 (ko) * 2021-12-08 2023-06-15 (주) 팜젠사이언스 벤즈이미다졸 유도체 화합물 및 이의 용도
KR20230114163A (ko) 2022-01-24 2023-08-01 엠에프씨 주식회사 칼륨 경쟁적 위산분비억제제 계열 약물의 신규한 무정형 고체분산체 및 그의 제조방법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005042485A1 (en) * 2003-10-30 2005-05-12 Sk Chemicals, Co., Ltd. Acid added salts of amlodipine
EP1695973A1 (en) * 2005-02-24 2006-08-30 Neuro3D Ocaperidone salt and pharmaceutical compositions containing the same
ATE442140T1 (de) 2005-06-14 2009-09-15 Raqualia Pharma Inc Chroman-substituierte benzimidazolderivate als säurepumpenantagonisten
ATE471319T1 (de) 2005-12-19 2010-07-15 Raqualia Pharma Inc Chromansubstituierte benzimidazole und ihre verwendung als säurepumpenhemmer
EP2318411A2 (en) * 2008-07-03 2011-05-11 Ratiopharm GmbH Crystalline salts of sitagliptin
TWI447108B (zh) * 2009-01-16 2014-08-01 Exelixis Inc Ｎ－（４－｛〔６，７雙（甲氧基）喹啉－４－基〕氧基｝苯基）－ｎ’－（４－氟苯基）環丙烷－１，１－二甲醯胺之蘋果酸鹽及其結晶型
US8648080B2 (en) * 2009-07-09 2014-02-11 Raqualia Pharma Inc. Acid pump antagonist for the treatment of diseases involved in abnormal gastrointestinal motility
KR101684053B1 (ko) * 2015-01-20 2016-12-08 씨제이헬스케어 주식회사 벤즈이미다졸 유도체의 신규 결정형 및 이의 제조방법
KR102262743B1 (ko) 2017-07-07 2021-06-09 에이치케이이노엔 주식회사 주사용 조성물

Also Published As

Publication number Publication date
JP2019529557A (ja) 2019-10-17
CN109769392A (zh) 2019-05-17
EP3517528B1 (en) 2021-09-01
US20210292307A1 (en) 2021-09-23
TWI659028B (zh) 2019-05-11
EP3517528A4 (en) 2020-05-20
US11535610B2 (en) 2022-12-27
CN109769392B (zh) 2022-06-24
EP3517528A1 (en) 2019-07-31
US20230192670A1 (en) 2023-06-22
PH12019500602A1 (en) 2019-11-11
MX2019003171A (es) 2019-06-10
TW201815786A (zh) 2018-05-01
MY197242A (en) 2023-06-07
JP6814891B2 (ja) 2021-01-20
ES2896802T3 (es) 2022-02-25
US20240150331A1 (en) 2024-05-09
US11912690B2 (en) 2024-02-27
JOP20170172A1 (ar) 2019-01-30
KR101829706B1 (ko) 2018-02-19
WO2018056697A1 (ko) 2018-03-29
AR109679A1 (es) 2019-01-09
JOP20170172B1 (ar) 2022-03-14

Similar Documents

Publication Publication Date Title
BR112019005505A2 (pt) sal pidolato ou sal malato, composição farmacêutica, método para preparar um sal, uso de quantidade terapeuticamente eficaz de sal e uso de um sal pidolato ou sal malato
BR112019024831A2 (pt) composto, sal, solvato ou pró-droga, composição farmacêutica, método de tratamento ou prevenção de uma doença, método para inibir o nlrp3
BR112018015474A2 (pt) agonista de fxr derivado de esteroide
BR112018002499A2 (pt) método de preparação de um composto da fórmula (a) ou um seu sal, solvato ou conjugado de aminoácido farmaceuticamente aceitável, composto produzido pelo método e composição farmacêutica
BR112017009601A2 (pt) derivados de aminoácidos e seus usos
BR112018015289A2 (pt) compostos de benzopirazol e análogos dos mesmos
BR112015018738A8 (pt) compostos de tetra-hidropirrolotiazina, seus usos, e composição farmacêutica
MX2016001096A (es) Sales de dasatinib en forma amorfa.
BR112015026478A2 (pt) derivados de dolastatina 10 e auristatinas
BR112015020639A2 (pt) composição de glifosato para misturas de tanque dicamba com volatilidade melhorada
NZ729037A (en) Carboxylic acid compound, method for preparation thereof, and use thereof
BR112018001869A2 (pt) método para preparação de ácidos biliares e derivados dos mesmos
BR112015006558A2 (pt) composição farmacêutica, processo para preparar uma composição farmacêutica, uso de uma composição farmacêutica, e, método para prevenir ou tratar doenças causadas por retrovírus
BR112014026266A2 (pt) derivado de quinazolidinadiona
BR112016013874A2 (pt) Fenil-triazolo-piridina, seus usos, seus processo de produção e seus intermediários, e composição farmacêutica
BR112019007763A2 (pt) composto de fórmula, composição farmacêutica, métodos para tratar uma doença ou condição, para tratar dores, para diminuir o fluxo de íons e para tratar prurido, uso de um composto e invenção
AR079213A1 (es) Procedimiento para tratar emulsiones agua/ aceite
MX2016001095A (es) Sales de dasatinib en forma cristalina.
BR112014026305A2 (pt) derivado de quinazolidinadiona
AR100694A1 (es) Compuestos de 1,3,4-tiadiazol y uso de los mismos para el tratamiento del cáncer
BR112015026967A8 (pt) fenoxietil di-hidro-1h-isoquinolina, seus usos, e composição farmacêutica
BR112020008258B8 (pt) Compostos de biarila substituída ou seus sais farmaceuticamente aceitáveis, sua composição e seu uso como inibidores de indoleamina 2,3-dioxigenase (ido)
BR112021023563A2 (pt) Sais farmaceuticamente aceitáveis de [2-(3-fluoro-5-metano-sulfonilfenóxi)etil](propil) amina e usos dos mesmos
BR112019005456A2 (pt) composição farmacêutica e método para tratamento de esteatose hepática não alcoólica
PL420378A1 (pl) Stabilizowany roztwór na bazie substancji czynnych, sposób otrzymywania stabilizowanego roztworu substancji czynnych, kompozycja farmaceutyczna na bazie stabilizowanego roztworu substancji czynnych (dwa warianty)

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B25D Requested change of name of applicant approved

Owner name: HK. INNO.N CORPORATION (KR)

B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/09/2017, OBSERVADAS AS CONDICOES LEGAIS